Mina K. Chung, MD, is the President of Heart Rhythm Society and a clinical cardiac electrophysiologist and translational scientist at the Cleveland Clinic. Her research aims to accelerate bringing basic advances in arrhythmia research back to the bedside. After early work discovering cytokines IL-1 and TNF that inhibit contractility in cardiomyocytes and a role for inflammation in atrial fibrillation (AF), she and her team contributed biorepositories to AF genetics discoveries, made functional, causative linkages for several AF risk loci, and applied iPSC-derived cardiomyocyte and AI approaches to multi-omics for therapeutic discovery and patient-specific analyses. She leads an AHA sponsored clinical trial testing genomically based drug and lifestyle modifications for AF and NIH Program Project studies of AF from genes to treatment. She also works actively with AHA and HRS to promote new approaches to accelerate acute detection and deployment for sudden cardiac arrest. Dr. Chung was Chair of the 2020 AHA Scientific Statement on lifestyle and risk factor modification for AF and the 2023 HRS Guideline on Cardiac Physiologic Pacing, and Vice Chair of the 2023 ACC/AHA/ACCP/HRS AF guideline. She has served as Chair of the AHA ECG/Arrhythmia and Data Science and Precision Medicine Committees, Clinical Science Lead for the AHA Committee on Scientific Sessions Program, and Director of the AHA COVID-19 Research Grants Coordinating Center. She has been named in Best Doctors in America since 2001 and has received the Cleveland Clinic Research Mentor, Clinical Research, and Excellence in Research awards, an AHA Bringing Science to Life Award, and the AHA Clinical Cardiology Council Distinguished Achievement Award.